ASCO Annual Meeting

Annual Meeting of American Society of Clinical Oncology (ASCO)

Chicago, June 3 - June 7, 2011

Investor Updates

  • Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations read more
  • Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer read more
  • Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse read more
  • Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO read more
  • MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse read more
  • Roche Analyst Event at ASCO 2011 read more

More Information

Roche ASCO Planner

ASCO

ASCO Abstracts

ASCO ePlanner

Invitation

Webcast replay

Analyst briefing on data presented at ASCO: Sunday, June 5

Presentation

Download mp3 file

Highlights:

  • Vemurafenib in advanced melanoma, BRIM3 study
    Antoni Ribas, MD, PhD, Associate Professor, Department of Medicine, 
    Division of Hematology/Oncology, University of California Los Angeles (UCLA) School of Medicine
  • Oncology pipeline update
    Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development
  • Avastin in relapsed ovarian cancer, OCEANS study
    Jakob Dupont, M.D., Global Medical Director, Avastin
  • Moving the standard of care through PHC – new opportunities for Roche
    Pascal Soriot, Chief Operating Officer Roche Pharmaceuticals